Bluejay Diagnostics completed commercial-scale production of polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6).
Both types of antibodies met internal performance criteria for clinical and potential commercial applications.
Bluejay estimates material to support over nine million Symphony cartridges; capable of producing more antibodies as needed.
Antibody Production Completion
Bluejay announced completion of commercial-scale production of IL-6 antibodies for clinical and commercial purposes.
Inventory Estimates
The company estimates having enough material for over nine million Symphony cartridges and can produce additional antibodies as required.
Symphony Development
Symphony remains under development, pending validation, regulatory review, and clearance.
- The completion of commercial-scale antibody production signifies progress towards advancing clinical and commercial applications.
- Inventory estimates indicate sufficient material availability for multiple Symphony cartridges, enhancing manufacturing potential.
- Ongoing development of Symphony reflects Bluejay's commitment to expanding its diagnostic capabilities in the medical field.
Bluejay Diagnostics' achievement in completing commercial-scale IL-6 antibody production showcases its dedication to advancing medical diagnostics. The company's focus on Symphony's development demonstrates a commitment to improving patient outcomes through innovative technology.